Freek W A Verheugt, MD, PhD

Freek W A Verheugt, MD, PhD

Professor of Cardiology

Chairman of the Department of Cardiology

Heartcenter of the University Medical Center

Nijmegen, The Netherlands

Related Videos

In the subpopulation of high-risk patients—individuals with post-ACS, patients with diabetes, post-PCI and others—is there enough compelling evidence from the PCSK9 trials that the “LDL hypothesis” is a proven fact? Video

In the subpopulation of high-risk patients—individuals with post-ACS, patients with diabetes, post-PCI and others—is there enough compelling evidence from the PCSK9 trials that the “LDL hypothesis” is a proven fact?

How have the results of ODYSSEY Outcomes—especially as they relate to progressive CV risk reductions in patients with high LDL-C levels who achieve target levels of 50 mg/dL or less—support the “treat-to-target” approach to lipid management? Video

How have the results of ODYSSEY Outcomes—especially as they relate to progressive CV risk reductions in patients with high LDL-C levels who achieve target levels of 50 mg/dL or less—support the “treat-to-target” approach to lipid management?

What would your approach be to a 57-year-old man with an LDL-C of 70 mg/dL who has recently had an ACS event and now develops recurrent ACS, or a new stent thrombosis? Does ODYSSEY Outcomes provide any evidence-based guidance? Video

What would your approach be to a 57-year-old man with an LDL-C of 70 mg/dL who has recently had an ACS event and now develops recurrent ACS, or a new stent thrombosis? Does ODYSSEY Outcomes provide any evidence-based guidance?

From your perspective as a medical cardiologist, what impact should the reductions in associated overall mortality reported with alirocumab in the ODYSSEY Outcomes Trial have on selecting a PCSK9 inhibitor? Video

From your perspective as a medical cardiologist, what impact should the reductions in associated overall mortality reported with alirocumab in the ODYSSEY Outcomes Trial have on selecting a PCSK9 inhibitor?

Based on the ODYSSEY Outcomes Trial, which enrolled primarily patients with post-ACS, which subset of patients managed in a medical cardiology practice should be thoroughly evaluated for CV risk reduction benefits accruing to PCSK9 inhibitors? Video

Based on the ODYSSEY Outcomes Trial, which enrolled primarily patients with post-ACS, which subset of patients managed in a medical cardiology practice should be thoroughly evaluated for CV risk reduction benefits accruing to PCSK9 inhibitors?

As the cost and institutional barriers to deploying PCSK9 inhibitors become less onerous, which patients in a medical cardiology practice represent the most attractive candidates for these agents and their profound LDL-C lowering effects? Video

As the cost and institutional barriers to deploying PCSK9 inhibitors become less onerous, which patients in a medical cardiology practice represent the most attractive candidates for these agents and their profound LDL-C lowering effects?